

Patient - PACT

New Clinical Trial and Research



Study title	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease (RAILD)
Trial synopsis	The drug pirfenidone is known to help patients with IPF, however its effect on other scarring lung conditions is unknown. This research study is designed to find out if pirfenidone can help people with Rheumatoid Arthritis and Interstitial Lung Disease (RA-ILD). without causing too many side effects. It will compare pirfenidone to placebo. The placebo looks exactly like pirfenidone, but contains no pirfenidone. There are a total of 9 study visits over 14 months when you will need to attend the site for study related assessments.
Investigational medicinal product	Pirfenidone(oral)/Placebo(oral)
Disease target	Patients With Rheumatoid Arthritis Interstitial Lung Disease (RAILD)
Sponsor	Brigham and Women's Hospital USA
Duration	Up to 60 weeks
Trial Status	Recruiting
Lead site	The Prince Charles Hospital QLD
Additional sites	Royal Prince Alfred Hospital NSW, The Alfred Hospital VIC
Contact	pactcoordinator@cre-pf.org.au